Synonyms: compound 14 [PMID: 27117263]
Compound class:
Synthetic organic
Comment: PKCθ inhibitor 14 was developed using structure-based drug design [1]. The compound is described as being selective for PKCθ, over other kinases, including related PKC isoforms.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
PKCθ inhibitor 14 inhibits IL-2 production in vitro and in vivo [1]. IC50 is 11nM in a human whole blood IL-2 assay. PKCθ inhibitor 14 exhibits IC50 values >10nM for PKCα, PKCβ, PKC, CLK, GSK-3β and TrkA, values which are ~ 40-fold higher than for PKCθ, but could be high enough to cause off-target effects. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|